GlassScriptPhysician profile
James T Love
NPI 1356322556
$6,544.45
in general payments reported to CMS, 2019-2025
32 companies · $2,223 in 2025
The $2,223 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $132 · 2021: $23.12 · 2022: $213 · 2023: $1,667 · 2024: $1,484 · 2025: $2,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,330 · Education: $42.25 · Travel and Lodging: $2.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,330.24 |
| Education | $42.25 |
| Travel and Lodging | $2.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,087.68 | 2019-2025 | Fasenra, Tezspire, Bevespi Aerosphere |
| Genzyme Corporation | $1,056.80 | 2019-2025 | |
| Csl Behring | $944.32 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $605.24 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $368.43 | 2019-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $356.22 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $345.05 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $282.86 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $208.70 | 2022-2025 | Hyqvia, Cuvitru, Takhzyro |
| Shire North American Group INC | $169.79 | 2019 | |
| Optinose US, INC. | $154.45 | 2019-2025 | |
| Pfizer INC. | $124.38 | 2019-2025 | |
| Kaleo, INC. | $98.76 | 2019-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $83.72 | 2023-2025 | Orladeyo |
| Organon LLC | $78.87 | 2025 | Vtama, Nexplanon |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $76.50 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $52.73 | 2022-2023 | |
| Abbvie INC. | $52.49 | 2022 | |
| Amarin Pharma, INC. | $50.03 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $43.77 | 2019-2025 | |
| Leo Pharma INC. | $41.35 | 2025 | Anzupgo |
| Greer Laboratories, INC. | $41.20 | 2022-2025 | Oralair |
| Mylan Specialty L.P. | $40.31 | 2023-2024 | Yupelri |
| Alk-Abello, INC | $29.94 | 2019 | |
| Galderma Laboratories, L.P. | $27.77 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $24.37 | 2023 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.01 | 2023 | Spiriva Respimat |
| Merck Sharp & Dohme LLC | $18.74 | 2023 | |
| Hikma Pharmaceuticals USA | $17.63 | 2025 | Ryaltris |
| Nestle Healthcare Nutrition INC. | $16.68 | 2023 | |
| Grifols USA, LLC | $13.63 | 2019 | |
| Inogen, INC. | $9.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.